CNTA · Centessa Pharmaceuticals plc · Stock research

Current Thesis

Nothing in the last month reopened this. Eli Lilly's UK scheme of arrangement — $38.00 cash per share plus one non-transferable contingent value right worth up to $9.00 — became effective on 2026-06-24 after the High Court of England and Wales sanctioned it on 2026-06-22; the acquirer vehicle was LDH XV Corporation, a wholly owned Lilly subsidiary. The final Nasdaq ADS session was 2026-06-23. The only genuinely new filing since the prior note is the Form 15-12G dated 2026-07-06 on SEC EDGAR, which suspends the reporting obligations and starts the clock on termination of registration. The only genuinely new news is class-level and lands elsewhere: on 2026-08-05 the FDA approved Takeda's ORZEYFUL (oveporexton) for narcolepsy type 1, the first approved OX2R agonist. That event moves Takeda, Alkermes and Lilly. It cannot move a security that no longer trades.

Bullish and bearish views on Centessa Pharmaceuticals plc

The model's bull view on Centessa Pharmaceuticals plc (CNTA), in brief: The consideration cleared in full. No financing condition, no antitrust hang-up, no re-cut: sanction 2026-06-22, effective 2026-06-24, cash fixed at $38.00 per share (CNTA 8-K, 2026-06-24). The announcement print on 2026-03-31 was +45%, against a headline value around $7.8B and… The bear view: There is no instrument. Delisted 2026-06-24; Form 15-12G dated 2026-07-06. Any CNTA quote a data vendor still renders is the 2026-06-23 print sitting on a dead feed. The CVR is non-transferable. Record holders at the scheme hold a contingent claim of up to $9.00 across staged… Both cases follow in full.

Bull Case

• The consideration cleared in full. No financing condition, no antitrust hang-up, no re-cut: sanction 2026-06-22, effective 2026-06-24, cash fixed at $38.00 per share (CNTA 8-K, 2026-06-24). The announcement print on 2026-03-31 was +45%, against a headline value around $7.8B and roughly a 40% premium.
• The final tape carried a CVR mark. The last adjusted close, 2026-06-23, was $40.50 — above the $38.00 cash consideration, so the market was still assigning residual value to the up-to-$9.00 CVR into the close. That is an inference from the price relationship, not a disclosed CVR valuation.
• The mechanism got a regulatory precedent on 2026-08-05. FDA approval of oveporexton, an oral orexin-receptor-2 agonist, on the strength of two randomized double-blind placebo-controlled Phase 3 trials in 273 NT1 adults (Takeda, 2026-08-05), establishes that the class can clear a US review. ORX750's registrational path sits inside Lilly now, and the CVR milestones ride on it.
• The holder base did not fight. The 2026-06-12 shareholder vote passed with the Samlyn / Bain / Perceptive institutional register in place — no holdout campaign, no appraisal drama, no delayed effective date.

Bear Case

• There is no instrument. Delisted 2026-06-24; Form 15-12G dated 2026-07-06. Any CNTA quote a data vendor still renders is the 2026-06-23 print sitting on a dead feed.
• The CVR is non-transferable. Record holders at the scheme hold a contingent claim of up to $9.00 across staged milestone payments. It cannot be bought, sold, hedged or expressed after close, so no positive ORX750 outcome converts into a tradable move in this symbol.
• ORX750 is now a follower. With ORZEYFUL approved for NT1 on 2026-08-05 and Alkermes running the Phase 3 Brilliance program in NT1/NT2 with FDA Breakthrough Therapy designation for alixorexton, the commercial slope for a later OX2R entrant is steeper than it looked when the deal was struck on 2026-03-31.
• The sell-side marks are archaeology. Needham. Those were resets to deal price plus a thin CVR mark and have no live referent.

Setup & Price Structure

• Narrative state: DEAD, dated three ways — last trade 2026-06-23, scheme effective 2026-06-24, deregistration filing 2026-07-06. This is not a fading narrative; the price-discovery mechanism was removed.
• The technical snapshot is frozen, and reading it as momentum is a category error. The basis close of $40.50 is simultaneously the 52-week high (0.0% from high), the 3-month return of 45.2% is the 2026-03-31 announcement gap, and RSI(14) at 71.1 is the final session's residue. None of these update.
• Crowding and positioning observables, stated plainly: no float in public hands, so no short interest to cover and no squeeze mechanics; no earnings date, because reporting obligations were suspended with the Form 15; no insider Form 4s can print post-deregistration; no issuance risk, since the ATM program and the Oxford Finance loan were terminated at close. The absence of every standard positioning observable is itself the structural fact.
• Historical levels for the record: $38.00 cash was the anchor floor from 2026-03-31 onward; the $40–42 analyst marks bracketed cash plus risk-adjusted CVR; the pre-bid base sat around $27–28 and was the only real downside reference the deal-break tail ever had.

Catalyst Calendar (next 30 days)

• No dated catalyst falls inside the next 30 days for this security. There is no print, no vote, no listing event.
• ~2026-10-04 (est.) — termination of ADS registration takes effect on the standard 90-day path from the 2026-07-06 Form 15-12G filing. Administrative; it closes the last public-disclosure channel on the entity.
• ~2026-12-31 (est.) — ORX750 registrational/CRYSTAL-1 program progress, guided by pre-deal Centessa disclosure to H2 2026, now reported (if at all) through Lilly's pipeline table. Relevant to CVR milestone determination, not to a share price.
• Undated — Alkermes Brilliance Phase 3 readouts and any ORZEYFUL launch metrics from Takeda set the class benchmark ORX750 will be measured against.

What Would Change Our Mind

Only an unwind of the scheme itself would put a tradable CNTA share back on a US exchange — a court-ordered rescission of the 2026-06-22 sanction, or a Lilly decision to re-list the entity. Neither appears on any docket or filing as of 2026-08-08. Expressed as the gradeable condition the record grades: a daily close below $38.00 cannot print, because no US session exists to produce one; the last was 2026-06-23 at $40.50. Secondary conditions that would matter if the structure ever changed: a CVR milestone payment notice (which pays scheme record holders and creates no market exposure), or a re-registration filing reversing the 2026-07-06 Form 15-12G. Absent those, the correct stance toward this symbol is to stop treating it as a live name.

Correlation Notes

• Zero live beta to XBI / IBB. From 2026-03-31 to 2026-06-23 the ADS traded as a deal-pinned instrument with near-nil sector correlation; after 2026-06-24 there is no series to correlate.
• The orexin read-through has re-routed. Class sentiment now expresses through Takeda (ORZEYFUL approved 2026-08-05), Alkermes (alixorexton, Phase 3 Brilliance, Breakthrough Therapy designation in NT1) and Lilly (ORX750 as an acquired asset). CNTA is a source of read-through for those names, never a recipient.
• Deal-arb comp: the 2026-03-31 tape that lifted CNTA also carried Apellis on the Biogen bid at $41/share — a reminder that the mid-cap biotech takeout window of spring 2026 was the driver of the move, and that window's later entries, not this one, are where the analog is still live.